WST Stock Recent News

West Pharmaceutical Services, Inc. (NYSE:WST ) Q4 2024 Earnings Conference Call February 13, 2025 9:00 AM ET Company Participants John Sweeney - Vice President of Investor Relations Eric Green - Chairman, President & Chief Executive Officer Bernard Birkett - Senior Vice President & Chief Financial Officer Conference Call Participants Michael Ryskin - BofA Global Research Lawrence Solow - CJS Securities Patrick Donnelly - Citigroup Inc. Paul Knight - KeyBanc Capital Markets Matthew Larew - William Blair & Company Justin Bowers - Deutsche Bank David Windley - Jefferies Jacob Johnson - Stephens Inc. Operator Thank you for standing by and welcome to West Pharmaceuticals Fourth Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.

West Pharmaceutical Services Inc.'s stock tumbled 33% Thursday, to lead S&P 500 decliners, after the manufacturer of injectable-pharmaceutical packaging and delivery systems offered guidance for 2025 that was well below expectations.

On Thursday, West Pharmaceutical Services, Inc. WST reported a fourth-quarter adjusted EPS of $1.82, beating the consensus of $1.72.

West Pharmaceutical Services forecast full-year profit and revenue below Wall Street estimates on Thursday due to a strong dollar and as the medical equipment maker's clients reduce inventory levels, sending its shares down 18% premarket.

West Pharmaceutical Services (WST) came out with quarterly earnings of $1.82 per share, beating the Zacks Consensus Estimate of $1.75 per share. This compares to earnings of $1.83 per share a year ago.

- Conference Call Scheduled for 9 a.m. EDT Today - EXTON, Pa.

West Pharmaceutical Services WST is scheduled to release fourth-quarter 2024 results on Feb. 13, before the opening bell. In the last reported quarter, the company delivered an earnings beat of 22.52%.

EXTON, Pa. , Jan. 30, 2025  /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST),  global leader in innovative solutions for injectable drug administration, today announced that it will release fourth-quarter and full-year 2024 financial results before the market opens on Thursday, February 13, 2025, and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time.

EXTON, Pa. , Jan. 28, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, announced today that the Company's Board of Directors has approved a first-quarter 2025 dividend of $0.21 per share. The dividend will be paid on February 11, 2025, to shareholders of record as of February 7, 2025.

EXTON, Pa. , Jan. 22, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced the introduction of Daikyo PLASCAP® Ready-to-Use Validated (RUV) closures in a new nested format available in multiple configurations at this year's Pharmapack event in Paris, France.  This marks West's latest product offering supporting the needs of advanced therapies, one of the fastest growing areas, driven by continued innovation in cell and gene therapy treatments.